報價延遲最少15分鐘:2025/01/21 05:24 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.6255 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.71/--
|
|
企業價值
15.08M
|
| 資產負債 |
|
每股賬面淨值
1.28
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
122.11K
|
|
每股收益
0.20
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 05:24 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, andtelehealth-friendly POCTs powered by the AI Nose technology platform. |